Saar Anis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Saar Anis has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Amos D. Korczyn
Departments of Neurology, Physiology and Pharmacology, Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
4 shared publications- Hubert H. Fernandez
Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, USA
4 shared publications Sharon Hassin-Baer
Neurological Department, Movement Disorders Institute, Sheba Medical Center, Ramat Gan, Israel
4 shared publicationsSimon Lassman
Neurological Department, Movement Disorders Institute, Sheba Medical Center, Ramat Gan, Israel
4 shared publicationsTsvia Fay-Karmon
Neurological Department, Movement Disorders Institute, Sheba Medical Center, Ramat Gan, Israel
4 shared publications- Camila Callegari Piccinin
Center for Neurological Restoration, Cleveland Clinic Foundation, Cleveland, OH, USA
3 shared publications
Latest Publications
- Open Access
Cognitive Performance in Prodromal Neuronal α-Synuclein Disease
Importance: Cognitive abnormalities may emerge during prodromal neuronal α-synuclein disease (NSD), but their domain specificity and longitudinal course are uncertain. Objective: To characterize baseline cognition and longitudinal change in prodromal NSD compared with healthy controls, NSD-negative genetic carriers, and sporadic Parkinson disease (PD). Design: Longitudinal cohort study using Parkinson’s Precision Medicine Initiative (PPMI) data, with first visits from July 2010 through April 2026 and up to 4 years of follow-up. Setting: Multicenter cohort. Participants: Healthy controls (HC; n=244), GBA1 or LRRK2 nonmanifesting carriers without NSD (n=323), prodromal NSD participants recruited through hyposmia or isolated rapid eye movement sleep behavior disorder cohorts (n=1640), and sporadic PD (n=824). Exposures: NSD status and clinical cohort. Main Outcomes and Measures: Cognitive summary scores for verbal memory, executive function, processing speed, language, and visuospatial function, and PPMI-defined mild cognitive impairment (MCI). Models adjusted for age, sex, education, and APOE ε4 status. Results: Among 3031 participants (mean [SD] age, 66.6 [7.0] years; 1322 female [43.6%]), prodromal NSD participants had lower baseline verbal-memory performance than HC (adjusted difference, −0.20 SD; 95% CI, −0.34 to −0.07; adjusted P = .007); NSD-negative genetic carriers did not differ from HC. No other cognitive domain was lower than HC at baseline or longitudinally. In the primary age-adjusted analysis, verbal-memory trajectory differed from HC over 4 years ( P = .009), whereas in a smaller age-matched sensitivity subset through year 3, it did not ( P = .62); the baseline difference persisted (adjusted difference, −0.28 SD; 95% CI, −0.46 to −0.10; P = .003). Adjusted MCI probability increased from 10.2% to 15.1% in prodromal NSD, compared with 8.4% to 5.0% in HC and 13.4% to 17.7% in PD. The increase was greater than in HC (ratio of annual odds ratios, 1.28; 95% CI, 1.04 to 1.58; adjusted P = .04) but not PD ( P = .62). Conclusions and Relevance: Prodromal NSD was associated with modestly lower verbal memory and increasing MCI probability relative to HC, without lower performance in other cognitive domains. The baseline verbal-memory difference was robust, whereas the longitudinal trajectory finding was not reproduced in the smaller age-matched sensitivity subset. Key Points: Question: What cognitive differences characterize prodromal neuronal α-synuclein disease, and how do they change over time? Findings: In this longitudinal cohort study of 3031 participants, prodromal neuronal α-synuclein disease was associated with lower verbal memory at baseline than healthy controls, while other cognitive domains were not lower. In the primary age-adjusted analysis, the verbal-memory trajectory differed from healthy controls over 4 years; in a smaller age-matched sensitivity subset through year 3, it did not differ significantly. Meaning: Cognitive involvement in prodromal neuronal α-synuclein disease may be detectable as a modest verbal-memory signal, while longitudinal changes require confirmation.
Open AccessCognitive Performance in Prodromal Neuronal α-Synuclein Disease
Importance: Cognitive abnormalities may emerge during prodromal neuronal α-synuclein disease (NSD), but their domain specificity and longitudinal course are uncertain. Objective: To characterize baseline cognition and longitudinal change in prodromal NSD compared with healthy controls, NSD-negative genetic carriers, and sporadic Parkinson disease (PD). Design: Longitudinal cohort study using Parkinson’s Precision Medicine Initiative (PPMI) data, with first visits from July 2010 through April 2026 and up to 4 years of follow-up. Setting: Multicenter cohort. Participants: Healthy controls (HC; n=244), GBA1 or LRRK2 nonmanifesting carriers without NSD (n=323), prodromal NSD participants recruited through hyposmia or isolated rapid eye movement sleep behavior disorder cohorts (n=1640), and sporadic PD (n=824). Exposures: NSD status and clinical cohort. Main Outcomes and Measures: Cognitive summary scores for verbal memory, executive function, processing speed, language, and visuospatial function, and PPMI-defined mild cognitive impairment (MCI). Models adjusted for age, sex, education, and APOE ε4 status. Results: Among 3031 participants (mean [SD] age, 66.6 [7.0] years; 1322 female [43.6%]), prodromal NSD participants had lower baseline verbal-memory performance than HC (adjusted difference, −0.20 SD; 95% CI, −0.34 to −0.07; adjusted P = .007); NSD-negative genetic carriers did not differ from HC. No other cognitive domain was lower than HC at baseline or longitudinally. In the primary age-adjusted analysis, verbal-memory trajectory differed from HC over 4 years ( P = .009), whereas in a smaller age-matched sensitivity subset through year 3, it did not ( P = .62); the baseline difference persisted (adjusted difference, −0.28 SD; 95% CI, −0.46 to −0.10; P = .003). Adjusted MCI probability increased from 10.2% to 15.1% in prodromal NSD, compared with 8.4% to 5.0% in HC and 13.4% to 17.7% in PD. The increase was greater than in HC (ratio of annual odds ratios, 1.28; 95% CI, 1.04 to 1.58; adjusted P = .04) but not PD ( P = .62). Conclusions and Relevance: Prodromal NSD was associated with modestly lower verbal memory and increasing MCI probability relative to HC, without lower performance in other cognitive domains. The baseline verbal-memory difference was robust, whereas the longitudinal trajectory finding was not reproduced in the smaller age-matched sensitivity subset. Key Points: Question: What cognitive differences characterize prodromal neuronal α-synuclein disease, and how do they change over time? Findings: In this longitudinal cohort study of 3031 participants, prodromal neuronal α-synuclein disease was associated with lower verbal memory at baseline than healthy controls, while other cognitive domains were not lower. In the primary age-adjusted analysis, the verbal-memory trajectory differed from healthy controls over 4 years; in a smaller age-matched sensitivity subset through year 3, it did not differ significantly. Meaning: Cognitive involvement in prodromal neuronal α-synuclein disease may be detectable as a modest verbal-memory signal, while longitudinal changes require confirmation.
- Open Access
- 1 October 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 153
Disentangling amantadine response variability in levodopa related dyskinesias: Role of clinical and genetic factors
- 1 October 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 153
Open AccessDisentangling amantadine response variability in levodopa related dyskinesias: Role of clinical and genetic factors
- Open Access
- 1 September 2026
- Published by Elsevier in SSRN Electronic Journal
A Pilot Randomized Trial of Physical Therapy with Atomoxetine or Methylphenidate for Gait and Balance Impairment in Parkinson’s Disease (The TAME-PD Study)
Background: Gait impairment in Parkinson's disease (PD) responds poorly to dopaminergic therapy. Whether catecholaminergic augmentation of physical therapy (PT) improves outcomes has not been tested in randomized trials.Objective: To assess feasibility and preliminary effects of adding atomoxetine or methylphenidate to structured PT in PD.Methods: TAME-PD was a single-center, randomized, rater-blinded pilot trial. Participants were randomized to PT alone, PT + atomoxetine 10 mg/day, or PT + methylphenidate 20 mg/day for 12 weeks. The primary outcome was change in Mini-Balance Evaluation Systems Test (Mini-BESTest) score at week 12.Results: Of 23 randomized participants, 18 had complete baseline and week-12 Mini-BESTest data. The primary outcome did not differ significantly between groups (Kruskal-Wallis p=0.099). Nonetheless, median improvement was 4.0 points with atomoxetine + PT, 2.0 with PT alone, and 1.5 with methylphenidate + PT. The effect-size point estimate for atomoxetine + PT versus PT alone was large (Cliff's δ=0.54, 95% CI −0.08 to 0.86); 80% of atomoxetine participants achieved the 4-point minimal clinically important difference versus 29% with PT alone and 17% with methylphenidate + PT. In the mixed-effects model, atomoxetine + PT improved more than methylphenidate + PT (+2.26 points; p=0.033; Holm-adjusted p=0.26); neither medication differed significantly from PT alone. Pooled medication-arm analysis showed no advantage over PT alone (p=0.68).Conclusions: Although this under-enrolled pilot trial was not conclusive, participants who received atomoxetine + PT showed greater median improvement in balance. These preliminary findings support further study of atomoxetine as a PT adjunct in PD with gait instability.
- 1 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Pilot Randomized Trial of Physical Therapy with Atomoxetine or Methylphenidate for Gait and Balance Impairment in Parkinson’s Disease (The TAME-PD Study)
Background: Gait impairment in Parkinson's disease (PD) responds poorly to dopaminergic therapy. Whether catecholaminergic augmentation of physical therapy (PT) improves outcomes has not been tested in randomized trials.Objective: To assess feasibility and preliminary effects of adding atomoxetine or methylphenidate to structured PT in PD.Methods: TAME-PD was a single-center, randomized, rater-blinded pilot trial. Participants were randomized to PT alone, PT + atomoxetine 10 mg/day, or PT + methylphenidate 20 mg/day for 12 weeks. The primary outcome was change in Mini-Balance Evaluation Systems Test (Mini-BESTest) score at week 12.Results: Of 23 randomized participants, 18 had complete baseline and week-12 Mini-BESTest data. The primary outcome did not differ significantly between groups (Kruskal-Wallis p=0.099). Nonetheless, median improvement was 4.0 points with atomoxetine + PT, 2.0 with PT alone, and 1.5 with methylphenidate + PT. The effect-size point estimate for atomoxetine + PT versus PT alone was large (Cliff's δ=0.54, 95% CI −0.08 to 0.86); 80% of atomoxetine participants achieved the 4-point minimal clinically important difference versus 29% with PT alone and 17% with methylphenidate + PT. In the mixed-effects model, atomoxetine + PT improved more than methylphenidate + PT (+2.26 points; p=0.033; Holm-adjusted p=0.26); neither medication differed significantly from PT alone. Pooled medication-arm analysis showed no advantage over PT alone (p=0.68).Conclusions: Although this under-enrolled pilot trial was not conclusive, participants who received atomoxetine + PT showed greater median improvement in balance. These preliminary findings support further study of atomoxetine as a PT adjunct in PD with gait instability.
- Open Access
- 1 September 2026
- Published by Wiley in Movement Disorders Clinical Practice
Lower Urinary Tract Symptoms as Diagnostic Clues in Parkinsonism: A Practical Framework for Neurologists
Background: Lower urinary tract symptoms (LUTS) are among the most prevalent nonmotor complaints across the parkinsonian spectrum, yet they remain underutilized as diagnostic and management signals in neurology practice. Although prior reviews have characterized disease‐specific patterns of urinary dysfunction, and recent guidelines address neurogenic LUTS broadly, no prior framework has explicitly focused on how the practicing neurologist can interpret LUTS as part of the diagnostic workup and integrate them into disease‐specific management across parkinsonian disorders. Methods: The aim of the review was to provide a neurology‐centered narrative review reframing LUTS as diagnostic clues in parkinsonism and to propose a practical clinical evaluation framework for neurologists. We conducted a narrative review of published literature on LUTS across parkinsonian disorders, identified through PubMed/MEDLINE searches through March 2026, supplemented by manual review of reference lists and relevant guidelines. Results: Disease‐specific LUTS patterns can carry diagnostic relevance that can inform the neurologic differential diagnosis. Early urinary retention or elevated postvoid residual volume should raise suspicion for multiple system atrophy. Nocturia in Parkinson's disease is frequently multifactorial, requiring stepwise evaluation of dopaminergic timing, sleep disorders, nocturnal polyuria, and fluid shifts before bladder‐directed therapy is initiated. LUTS may interact with mobility and falls through urgency‐freezing convergence and nocturia‐orthostatic hypotension overlap. Antimuscarinic agents carry compounded risks of cognitive impairment, delirium, and falls in this population. Conclusions: A pragmatic framework using symptom classification, postvoid residual measurement, red flag identification, and targeted pharmacologic guidance can support safe and timely LUTS management within routine neurology practice.
- 1 September 2026
- Published by Wiley in Movement Disorders Clinical Practice
Open AccessLower Urinary Tract Symptoms as Diagnostic Clues in Parkinsonism: A Practical Framework for Neurologists
Background: Lower urinary tract symptoms (LUTS) are among the most prevalent nonmotor complaints across the parkinsonian spectrum, yet they remain underutilized as diagnostic and management signals in neurology practice. Although prior reviews have characterized disease‐specific patterns of urinary dysfunction, and recent guidelines address neurogenic LUTS broadly, no prior framework has explicitly focused on how the practicing neurologist can interpret LUTS as part of the diagnostic workup and integrate them into disease‐specific management across parkinsonian disorders. Methods: The aim of the review was to provide a neurology‐centered narrative review reframing LUTS as diagnostic clues in parkinsonism and to propose a practical clinical evaluation framework for neurologists. We conducted a narrative review of published literature on LUTS across parkinsonian disorders, identified through PubMed/MEDLINE searches through March 2026, supplemented by manual review of reference lists and relevant guidelines. Results: Disease‐specific LUTS patterns can carry diagnostic relevance that can inform the neurologic differential diagnosis. Early urinary retention or elevated postvoid residual volume should raise suspicion for multiple system atrophy. Nocturia in Parkinson's disease is frequently multifactorial, requiring stepwise evaluation of dopaminergic timing, sleep disorders, nocturnal polyuria, and fluid shifts before bladder‐directed therapy is initiated. LUTS may interact with mobility and falls through urgency‐freezing convergence and nocturia‐orthostatic hypotension overlap. Antimuscarinic agents carry compounded risks of cognitive impairment, delirium, and falls in this population. Conclusions: A pragmatic framework using symptom classification, postvoid residual measurement, red flag identification, and targeted pharmacologic guidance can support safe and timely LUTS management within routine neurology practice.
- Open Access
- 17 July 2026
- Published by Elsevier in SSRN Electronic Journal
A Pilot Randomized Trial of Physical Therapy with Atomoxetine or Methylphenidate for Gait and Balance Impairment in Parkinson’s Disease (The TAME-PD Study)
Background: Gait impairment in Parkinson's disease (PD) responds poorly to dopaminergic therapy. Whether noradrenergic augmentation of physical therapy (PT) improves outcomes has not been tested in a randomized trial.Objective: To evaluate the feasibility and preliminary efficacy of adding atomoxetine or methylphenidate to structured PT in PD.Methods: TAME-PD was a single-center, randomized, rater-blinded pilot trial. Participants with PD and gait impairment were randomized to PT alone, PT + atomoxetine 10 mg/day, or PT + methylphenidate 20 mg/day for 12 weeks. The primary outcome was the change in Mini-Balance Evaluation Systems Test (Mini-BESTest) score at week 12. Analyses included Kruskal-Wallis tests, Cliff's delta, responder analysis, and linear mixed-effects models.Results: Of 23 randomized participants, 18 had complete baseline and week-12 Mini-BESTest data. Median Mini-BESTest improvement was 4.0 with atomoxetine + PT, 1.5 with methylphenidate + PT, and 2.0 with PT alone (p=0.099). The PT + atomoxetine-versus-PT alone effect size was large (Cliff's δ=0.54), and 80% of atomoxetine-medicated participants achieved the 4-point clinically important difference versus 29% with PT alone and 17% with PT + methylphenidate. In the longitudinal model, atomoxetine showed greater improvement than methylphenidate (+2.26 points; p=0.033; adjusted p=0.26 after Holm correction), whereas neither medication differed significantly from PT alone. The pooled medication-arm analysis showed no advantage over PT alone (+0.38 points; p=0.68).Conclusions: Although this under-enrolled pilot trial was not conclusive, participants who received atomoxetine with PT tended to improve balance. These preliminary findings support further study of atomoxetine as a PT adjunct in PD with gait instability.
- 17 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Pilot Randomized Trial of Physical Therapy with Atomoxetine or Methylphenidate for Gait and Balance Impairment in Parkinson’s Disease (The TAME-PD Study)
Background: Gait impairment in Parkinson's disease (PD) responds poorly to dopaminergic therapy. Whether noradrenergic augmentation of physical therapy (PT) improves outcomes has not been tested in a randomized trial.Objective: To evaluate the feasibility and preliminary efficacy of adding atomoxetine or methylphenidate to structured PT in PD.Methods: TAME-PD was a single-center, randomized, rater-blinded pilot trial. Participants with PD and gait impairment were randomized to PT alone, PT + atomoxetine 10 mg/day, or PT + methylphenidate 20 mg/day for 12 weeks. The primary outcome was the change in Mini-Balance Evaluation Systems Test (Mini-BESTest) score at week 12. Analyses included Kruskal-Wallis tests, Cliff's delta, responder analysis, and linear mixed-effects models.Results: Of 23 randomized participants, 18 had complete baseline and week-12 Mini-BESTest data. Median Mini-BESTest improvement was 4.0 with atomoxetine + PT, 1.5 with methylphenidate + PT, and 2.0 with PT alone (p=0.099). The PT + atomoxetine-versus-PT alone effect size was large (Cliff's δ=0.54), and 80% of atomoxetine-medicated participants achieved the 4-point clinically important difference versus 29% with PT alone and 17% with PT + methylphenidate. In the longitudinal model, atomoxetine showed greater improvement than methylphenidate (+2.26 points; p=0.033; adjusted p=0.26 after Holm correction), whereas neither medication differed significantly from PT alone. The pooled medication-arm analysis showed no advantage over PT alone (+0.38 points; p=0.68).Conclusions: Although this under-enrolled pilot trial was not conclusive, participants who received atomoxetine with PT tended to improve balance. These preliminary findings support further study of atomoxetine as a PT adjunct in PD with gait instability.
- Open Access
- 20 June 2026
- Published by Elsevier in SSRN Electronic Journal
A Clinical Workflow for Continuous Subcutaneous Foslevodopa/Foscarbidopa Therapy in Advanced Parkinson's Disease: Experience From the First 50 Patients
Background: Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion is a new device-aided therapy for advanced Parkinson's disease (PD), but real-world implementation experience, particularly in patients with prior deep brain stimulation (DBS), remains limited.Objectives: To describe a standardized clinical workflow for LDp/CDp implementation and report outcomes from the first 50 consecutive patients.Methods: Quality improvement report based on retrospective chart review at a tertiary movement disorders center between January 2025 and April 2026. Clinical management lessons were synthesized into a reproducible implementation workflow, and clinical response was assessed using the Clinician Global Impression of Change (CGI-C).Results: Median age was 68 years, disease duration 14 years, and baseline levodopa equivalent daily dose 1,108 mg; 37 patients (74%) were male, 25 (50%) had prior DBS, and 6 (12%) had transitioned from levodopa-carbidopa intestinal gel. Median time from referral to pump initiation was 78 days, and patients required a median of 4 visits to reach stable dosing. Manufacturer-predicted and final optimized base infusion rates were nearly identical (medians 0.38 vs 0.39 mL/hr), although individualized titration was required in most patients. The CGI-C indicated minimal-to-marked improvement in most patients. Forty-one patients (82%) remained on therapy; skin reactions occurred in 46%, six patients (12%) discontinued, and three (6%) died. Among DBS patients, median stimulation current decreased from 4.4 to 4.0 mA, with reductions in 7/25 (28%).Conclusions: A standardized workflow supported feasible LDp/CDp implementation in a DBS-enriched cohort, including integration with existing DBS therapy. This experience offers a practical framework for centers adopting this therapy.
- 20 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Clinical Workflow for Continuous Subcutaneous Foslevodopa/Foscarbidopa Therapy in Advanced Parkinson's Disease: Experience From the First 50 Patients
Background: Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion is a new device-aided therapy for advanced Parkinson's disease (PD), but real-world implementation experience, particularly in patients with prior deep brain stimulation (DBS), remains limited.Objectives: To describe a standardized clinical workflow for LDp/CDp implementation and report outcomes from the first 50 consecutive patients.Methods: Quality improvement report based on retrospective chart review at a tertiary movement disorders center between January 2025 and April 2026. Clinical management lessons were synthesized into a reproducible implementation workflow, and clinical response was assessed using the Clinician Global Impression of Change (CGI-C).Results: Median age was 68 years, disease duration 14 years, and baseline levodopa equivalent daily dose 1,108 mg; 37 patients (74%) were male, 25 (50%) had prior DBS, and 6 (12%) had transitioned from levodopa-carbidopa intestinal gel. Median time from referral to pump initiation was 78 days, and patients required a median of 4 visits to reach stable dosing. Manufacturer-predicted and final optimized base infusion rates were nearly identical (medians 0.38 vs 0.39 mL/hr), although individualized titration was required in most patients. The CGI-C indicated minimal-to-marked improvement in most patients. Forty-one patients (82%) remained on therapy; skin reactions occurred in 46%, six patients (12%) discontinued, and three (6%) died. Among DBS patients, median stimulation current decreased from 4.4 to 4.0 mA, with reductions in 7/25 (28%).Conclusions: A standardized workflow supported feasible LDp/CDp implementation in a DBS-enriched cohort, including integration with existing DBS therapy. This experience offers a practical framework for centers adopting this therapy.
- 16 June 2026
- Published by SAGE Publications in Cannabis & Cannabinoid Research
Exploratory Prospective Study of Self-Titrated Medical Cannabis for Nonmotor Symptoms in Parkinson’s Disease
Background: Medical cannabis (MC) has emerged as a potential therapy for Parkinson’s disease (PD), targeting motor and nonmotor symptoms (NMS), such as pain, sleep disturbance, and urinary dysfunction. Cannabinoid receptors in central and peripheral systems, including the bladder, provide a mechanistic basis for symptom modulation. This study evaluated the feasibility, safety, and preliminary clinical effects of MC on NMS in PD within a real-world, regulated framework. Methods: In this single-center, open-label, prospective cohort, 68 patients with PD initiating MC were assessed at baseline and at 3 months using validated scales: the Non-Motor Symptoms Scale (NMSS), King’s Parkinson’s Disease Pain Scale (KPPS), PD Sleep Scale-2 (PDSS-2), PD Quality-of-Life Questionnaire-8 (PDQ-8), and International Prostate Symptom Score (IPSS), along with 2-day urinary diaries. Participants used either cannabis oil extract or inflorescence products with varying THC/CBD (Δ 9 -tetrahydrocannabinol/cannabidiol) ratios. Adverse events and withdrawals were recorded. Cannabinoid composition was analyzed via ultra-high-performance liquid chromatography and correlated with clinical outcomes. Results: Fifty participants (mean age 65.6 ± 11.0 years; 68% male) completed follow-up. MC use was associated with improvements in NMSS total (Δ 14.5, p = 0.001), PDSS-2 (Δ 5.9, p < 0.001), KPPS (Δ 8.1, p = 0.004), PDQ-8 (Δ 1.5, p = 0.040), and the NMSS urinary domain (Δ 2.1, p = 0.050). Nighttime urinary frequency decreased (median Δ 0.5, p = 0.016), while daytime parameters were unchanged. No correlations were found between cannabinoid composition or THC/CBD enrichment type and clinical response. The dropout rate was 26.5%, mainly due to loss to follow-up. Conclusions: Short-term, self-titrated MC was feasible and appeared generally well tolerated in this open-label setting, suggesting potential benefits for pain, sleep, and nocturnal urinary frequency in PD. These exploratory findings warrant randomized controlled trials focused on these domains and incorporating standardized dosing, pharmacokinetic monitoring, and predefined cognitive safety assessments to determine efficacy, safety, and optimal dosing.
- 16 June 2026
- Published by SAGE Publications in Cannabis & Cannabinoid Research
Exploratory Prospective Study of Self-Titrated Medical Cannabis for Nonmotor Symptoms in Parkinson’s Disease
Background: Medical cannabis (MC) has emerged as a potential therapy for Parkinson’s disease (PD), targeting motor and nonmotor symptoms (NMS), such as pain, sleep disturbance, and urinary dysfunction. Cannabinoid receptors in central and peripheral systems, including the bladder, provide a mechanistic basis for symptom modulation. This study evaluated the feasibility, safety, and preliminary clinical effects of MC on NMS in PD within a real-world, regulated framework. Methods: In this single-center, open-label, prospective cohort, 68 patients with PD initiating MC were assessed at baseline and at 3 months using validated scales: the Non-Motor Symptoms Scale (NMSS), King’s Parkinson’s Disease Pain Scale (KPPS), PD Sleep Scale-2 (PDSS-2), PD Quality-of-Life Questionnaire-8 (PDQ-8), and International Prostate Symptom Score (IPSS), along with 2-day urinary diaries. Participants used either cannabis oil extract or inflorescence products with varying THC/CBD (Δ 9 -tetrahydrocannabinol/cannabidiol) ratios. Adverse events and withdrawals were recorded. Cannabinoid composition was analyzed via ultra-high-performance liquid chromatography and correlated with clinical outcomes. Results: Fifty participants (mean age 65.6 ± 11.0 years; 68% male) completed follow-up. MC use was associated with improvements in NMSS total (Δ 14.5, p = 0.001), PDSS-2 (Δ 5.9, p < 0.001), KPPS (Δ 8.1, p = 0.004), PDQ-8 (Δ 1.5, p = 0.040), and the NMSS urinary domain (Δ 2.1, p = 0.050). Nighttime urinary frequency decreased (median Δ 0.5, p = 0.016), while daytime parameters were unchanged. No correlations were found between cannabinoid composition or THC/CBD enrichment type and clinical response. The dropout rate was 26.5%, mainly due to loss to follow-up. Conclusions: Short-term, self-titrated MC was feasible and appeared generally well tolerated in this open-label setting, suggesting potential benefits for pain, sleep, and nocturnal urinary frequency in PD. These exploratory findings warrant randomized controlled trials focused on these domains and incorporating standardized dosing, pharmacokinetic monitoring, and predefined cognitive safety assessments to determine efficacy, safety, and optimal dosing.
- Open Access
- 11 February 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 145, 108234
Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center
- 11 February 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 145, 108234
Open AccessPhosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center
- 28 January 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 144, 108221
Lifting the veil: Interpreting phenotypic fluidity in functional movement disorders
- 28 January 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 144, 108221
Lifting the veil: Interpreting phenotypic fluidity in functional movement disorders
- 19 January 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 144, 108199
Introducing a workflow algorithm for adaptive DBS programming in Parkinson's disease
- 19 January 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 144, 108199
Introducing a workflow algorithm for adaptive DBS programming in Parkinson's disease